As part of an international clinical trial, Jacksonville-based Mayo Clinic in Florida has become the first U.S. site to target metastatic breast cancer with the radiopharmaceutical actinium-225. The ...

Eli Lilly › Great businesses have a habit of remaining so even when market volatility arises. The stock market is cyclical, ...

Mayo Clinic says the therapy uses an alpha-emitting radiopharmaceutical designed to target cancer cells precisely without ...

Mayo Clinic has treated the first person in the U.S. using a novel radioactive medicine for advanced breast cancer as part of ...

Overtreatment is considered harmful in terms of decreasing quality of life, wasting resources, and environmental damage.1–3 These risks are especially relevant when considering adjuvant chemotherapy ...

One relatively safe bet about how Pfizer's lineup will look different five years from now is that the company will be a ...

The BEAT Breast Cancer project is funded by the Pfizer Foundation, in collaboration with the Ministry of Health and the ...

DelveInsight's Triple-Negative Breast Cancer Market Insights report includes a comprehensive understanding of current ...

The triple-negative breast cancer market is expected to grow due to rising incidence rates, increasing awareness, advancements in targeted therapies, ongoing clinical trials, improved diagnostics ...

At a stroke, the data gives Celcuity a potential advantage over already-marketed oral PI3K inhibitors like Novartis' ...

The drug, gedatolisib, in combination with Pfizer's Ibrance and AstraZeneca's endocrine therapy Faslodex, reduced the risk of ...